FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome
CSTI-500 has received a Rare Pediatric Disease Designation (RPDD) from the FDA for the treatment of Prader-Willi Syndrome (PWS) in pediatric patients, according to ConSynance Therapeutics, Inc.1 Approximately 1 in 15,000 live births are impacted by PWS, a …